First approved by the FDA in the 1970s, combination products are used everyday in the form of inhalers and transdermal patches as new forms of patient care and treatment. According to Grand View Research, the combination products market is expected reach $177 billion by 2024.
Medical Device and Pharmaceutical R&D employees developing pharmaceuticals or combination products can learn about computational modeling and simulation for product designs like drug eluting stents, pre-filled syringes and pharmaceutical therapeutics in a complementary new webinar from Dassault Systèmes. Held on September 20 and hosted by Karl D’Souza, part of the Virtual Human Modeling group, the webinar will outline how to develop products that are:
• Safe, yet effective, • Structurally sound and reliable, • Easy to use with minimal discomfort.
Modeling and simulation has been used for decades to separately design and test medical devices and discover drug therapeutics. With the advent of physics-based, virtual human models combined with connected micro and macro simulation tools on a common platform, combination devices and pharmaceutical therapeutics can be studied in-silico and only the best design outcomes can be put forth in clinical trials.
Click here to attend this FREE webinar..
Suzanne is the lead communications person for Dassault Systemes in North America working out of Waltham, Mass. A Boston native, she's spent most of her career in B2B technology with an occasional foray into B2C. She really likes Wonder Woman.